FOLH1 and pachyonychia congenita: In preliminary findings with limited sample size and follow-up by our working group, we found significantly improved PSA progression-free survival (PFS) for patients that underwent SLNRT instead of SLND for PSMA-PET/CT-based nodal recurrent PC (7).